Goldman Sachs raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $44 and keeps a Sell rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics’ Earnings Call Highlights Success and Challenges
- PTC Therapeutics price target raised to $82 from $70 at RBC Capital
- PTC Therapeutics price target raised to $63 from $50 at TD Cowen
- PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs
- PTC Therapeutics price target raised to $80 from $68 at JPMorgan